{
    "clinical_study": {
        "@rank": "80629", 
        "arm_group": [
            {
                "arm_group_label": "Micellar curcumin", 
                "arm_group_type": "Experimental", 
                "description": "Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of micellar curcumin on inflammation\n      and lipid metabolism markers in subjects at risk for the metabolic syndrome."
        }, 
        "brief_title": "Micellar Curcumin and Metabolic Syndrome Biomarkers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metabolic Syndrome, Protection Against", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Total cholesterol > 5.2 mmol/L\n\n          -  LDL cholesterol > 3.4 mmol/L\n\n          -  Triglyceride > 2.26 mmol/L\n\n          -  CRP > 2 mg/L\n\n        Exclusion criteria:\n\n          -  Intake of drugs or dietary supplements\n\n          -  Pregnant women and breastfeeding mothers\n\n          -  Smokers\n\n          -  Previous illnesses such as heart attack, cancer or dementia\n\n          -  Addiction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925547", 
            "org_study_id": "0315679-HS3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Micellar curcumin", 
                "description": "80 mg micellar curcumin (oral) three times a day for six weeks", 
                "intervention_name": "Micellar curcumin", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Curcumin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stuttgart", 
                    "country": "Germany", 
                    "state": "Baden-W\u00fcrttemberg", 
                    "zip": "70599"
                }, 
                "name": "Institute of Biological Chemistry and Nutrition, University of Hohenheim"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Micellar Curcumin on Inflammation and Lipid Metabolism Markers", 
        "overall_official": {
            "affiliation": "University of Hohenheim", 
            "last_name": "Jan Frank, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Serum CRP in mg/L", 
            "measure": "C-reactive protein (CRP)", 
            "safety_issue": "No", 
            "time_frame": "At baseline and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925547"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Hohenheim", 
            "investigator_full_name": "Jan Frank", 
            "investigator_title": "Professor, Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Concentrations (in nmol/L) of curcumin and curcumin conjugates in plasma", 
                "measure": "Plasma curcumin concentrations", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum activity of ALT in U/L", 
                "measure": "Serum alanine transaminase activity", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Fasting blood glucose in mmol/L", 
                "measure": "Fasting blood glucose", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Plasma concentrations of TNF\u03b1 in pg/mL", 
                "measure": "Plasma tumor necrosis factor alpha", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum concentrations of uric acid in g/L", 
                "measure": "Serum uric acid", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Plasma concentrations of albumin in g/L", 
                "measure": "Plasma albumin", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum total cholesterol in mmol/L", 
                "measure": "Serum total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum triacylglycerols in mmol/L", 
                "measure": "Serum triacylglycerols", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum HDL cholesterol in mmol/L", 
                "measure": "Serum HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum LDL cholesterol in mmol/L", 
                "measure": "Serum LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum activity of AST in U/L", 
                "measure": "Serum aspartate transaminase activity", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum activity of gamma-GT in U/L", 
                "measure": "Serum gamma glutamyl transferase activity", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum activity of ALP in U/L", 
                "measure": "Serum alkaline phosphatase activity", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum concentrations of bilirubin in g/L", 
                "measure": "Serum bilirubin", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Plasma concentrations of IL-6 in pg/mL", 
                "measure": "Plasma interleukine 6", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum concentrations of insulin in pg/mL", 
                "measure": "Serum insulin", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Body weight in kg", 
                "measure": "Body weight", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Diastolic blood pressure in mmHg", 
                "measure": "Diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Serum concentrations of creatinine in g/L", 
                "measure": "Serum creatinine", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline and 6 weeks"
            }, 
            {
                "description": "Systolic blood pressure in mmHg", 
                "measure": "Systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 weeks"
            }
        ], 
        "source": "University of Hohenheim", 
        "sponsors": {
            "collaborator": {
                "agency": "German Federal Ministry of Education and Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Hohenheim", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}